Ray Dalio
IMCR icon

Ray Dalio’s Immunocore IMCR Stock Holding History

Ray Dalio’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$571K Buy
18,930
+8,978
+90% +$290K ﹤0.01% 864
2025
Q4 		$345K Buy
+9,952
New +$351K ﹤0.01% 998

Other funds holding IMCR

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ray Dalio's IMCR Position: Q1 2026 in Review

Ray Dalio increased its Immunocore (IMCR) stake by 90% in Q1 2026, buying an estimated $290K and bringing the position to 18,930 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Ray Dalio first reported a position in IMCR in Q4 2025 and has held it in 2 quarters since. 142 funds tracked by Wall St. Rank hold IMCR as of Q1 2026.

  • Ray Dalio held 18,930 shares of Immunocore worth $571K as of Q1 2026.
  • Ray Dalio bought 8,978 Immunocore shares in Q1 2026, an estimated $290K.
  • Immunocore made up ﹤0.01% of Ray Dalio's portfolio in Q1 2026, its #864 holding.
  • Ray Dalio first reported a position in Immunocore in Q4 2025 and has held it in 2 quarters since.
  • 142 funds tracked by Wall St. Rank held Immunocore as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.